JP2022532404A5 - - Google Patents

Info

Publication number
JP2022532404A5
JP2022532404A5 JP2021568319A JP2021568319A JP2022532404A5 JP 2022532404 A5 JP2022532404 A5 JP 2022532404A5 JP 2021568319 A JP2021568319 A JP 2021568319A JP 2021568319 A JP2021568319 A JP 2021568319A JP 2022532404 A5 JP2022532404 A5 JP 2022532404A5
Authority
JP
Japan
Prior art keywords
crystalline form
ray powder
powder diffraction
measured
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021568319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532404A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/054628 external-priority patent/WO2020230099A1/en
Publication of JP2022532404A publication Critical patent/JP2022532404A/ja
Publication of JP2022532404A5 publication Critical patent/JP2022532404A5/ja
Priority to JP2024045596A priority Critical patent/JP2024095697A/ja
Withdrawn legal-status Critical Current

Links

JP2021568319A 2019-05-16 2020-05-15 Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態 Withdrawn JP2022532404A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024045596A JP2024095697A (ja) 2019-05-16 2024-03-21 Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962848857P 2019-05-16 2019-05-16
US62/848,857 2019-05-16
US201962949599P 2019-12-18 2019-12-18
US62/949,599 2019-12-18
PCT/IB2020/054628 WO2020230099A1 (en) 2019-05-16 2020-05-15 Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024045596A Division JP2024095697A (ja) 2019-05-16 2024-03-21 Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態

Publications (2)

Publication Number Publication Date
JP2022532404A JP2022532404A (ja) 2022-07-14
JP2022532404A5 true JP2022532404A5 (https=) 2022-08-25

Family

ID=70775449

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568319A Withdrawn JP2022532404A (ja) 2019-05-16 2020-05-15 Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態
JP2024045596A Pending JP2024095697A (ja) 2019-05-16 2024-03-21 Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024045596A Pending JP2024095697A (ja) 2019-05-16 2024-03-21 Ｎ－［４－（クロロジフルオロメトキシ）フェニル］－６－［（３ｒ）－３－ヒドロキシピロリジン－１－イル］－５－（１ｈ－ピラゾール－５－イル）ピリジン－３－カルボキサミドの結晶性形態

Country Status (13)

Country Link
US (3) US11407735B2 (https=)
EP (1) EP3969117B1 (https=)
JP (2) JP2022532404A (https=)
KR (1) KR102945602B1 (https=)
CN (1) CN114144232A (https=)
AU (1) AU2020276701B2 (https=)
BR (1) BR112021022712A2 (https=)
CA (1) CA3139812A1 (https=)
CL (1) CL2021003011A1 (https=)
IL (1) IL287995A (https=)
MX (1) MX2021013970A (https=)
TW (2) TW202444706A (https=)
WO (1) WO2020230099A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
WO2021154980A1 (en) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of asciminib and processes for the preparation thereof
WO2022206937A1 (zh) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
CN114369085B (zh) * 2021-12-27 2023-01-03 武汉九州钰民医药科技有限公司 盐酸Asciminib的制备方法
WO2024100212A1 (en) 2022-11-10 2024-05-16 Synthon B.V. Crystalline form of asciminib hydrochloride
WO2024257116A1 (en) * 2023-06-13 2024-12-19 Natco Pharma Limited Novel polymorphic forms of asciminib and its pharmaceutical salts thereof
WO2025032514A1 (en) * 2023-08-07 2025-02-13 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of solid forms of n-[4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PE20161416A1 (es) * 2012-05-15 2017-01-08 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
RU2647421C2 (ru) 2012-12-27 2018-03-15 Зентива Саглык Урунлеры Сан. Ве Тыдж. А.Ш. Способ сухого гранулирования для получения композиций метформина в виде таблеток и его композиции
CA2954840A1 (en) 2014-07-25 2016-01-28 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
EP3292870A1 (en) 2016-09-08 2018-03-14 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Fibronectin for use in the treatment of leukemia
WO2018060843A1 (en) 2016-09-27 2018-04-05 Novartis Ag Surfactant systems for crystallization of organic compounds
US11065243B2 (en) 2017-10-27 2021-07-20 Sonic Master Limited Inhibitors of DUX4 induction for regulation of muscle function
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202444706A (zh) * 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Similar Documents

Publication Publication Date Title
JP2022532404A5 (https=)
TWI670270B (zh) 包含jak抑制劑之醫藥組合物
KR101151117B1 (ko) 경구 투여가능한 고체 제약 조성물의 제조 방법
JP7456721B2 (ja) ５－メチル－１－フェニル－２－（１ｈ）－ピリドンの顆粒製剤及びその製造方法
KR101257919B1 (ko) 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 경구용 고형 제제 및 이의 제조방법
CA2700844A1 (en) Stable imatinib compositions
PL211062B1 (pl) Kompozycja farmaceutyczna do podawania doustnegozawierająca flibanserynę oraz zastosowanie kompozycji
TW201211025A (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists
JP2020200348A (ja) 光安定性を向上したシロドシン含有着色錠剤
JP7378279B2 (ja) ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP2020132613A (ja) ラメルテオン含有固形製剤
JP2020180101A (ja) レベチラセタム含有医薬組成物の製造方法
JP7023600B2 (ja) シロドシン含有医薬組成物とその製造方法
KR101578627B1 (ko) 실로도신의 용출 특성이 향상된 약제학적 제제
JP2020152707A (ja) 安定化されたエソメプラゾールマグネシウム水和物含有腸溶性固形製剤
RU2024129605A (ru) Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида
KR101524264B1 (ko) 발사르탄 함유 경구용 약학 조성물
JP2015504913A (ja) 安定な非晶質のラルテグラビルカリウムプレミックス、及び、その調製方法
JP2021024820A (ja) 光安定性が向上した、ダサチニブ無水物フィルムコーティング錠剤
RU2021136800A (ru) Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида
JP7628020B2 (ja) アキシチニブを有効成分とする医薬錠剤
JP4684545B2 (ja) 溶出性の良好なイソキサゾール誘導体経口製剤
JP6199922B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
JP5065519B1 (ja) 結晶性アトルバスタチンカルシウム含有錠剤の製造方法
JP5563371B2 (ja) クエチアピンフマル酸塩含有経口用錠剤